← Back to Search

Group 1 for Glaucoma (IGDM Trial)

N/A
Waitlist Available
Led By George Hu, Ph.D.
Research Sponsored by Synabridge Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

To introduce a rapid and objective electrophysiological technique that can assess visual function in the magnocellular pathway, which is thought to be affected in early-stage glaucoma.

Eligible Conditions
  • Glaucoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Group 2Experimental Treatment1 Intervention
Glaucoma suspects
Group II: Group 1Experimental Treatment1 Intervention
Glaucoma Patients
Group III: Group 3Active Control1 Intervention
Controls

Find a Location

Who is running the clinical trial?

Synabridge CorporationLead Sponsor
Yale UniversityOTHER
1,919 Previous Clinical Trials
3,040,175 Total Patients Enrolled
2 Trials studying Glaucoma
17 Patients Enrolled for Glaucoma
University of Alabama at BirminghamOTHER
1,642 Previous Clinical Trials
2,332,389 Total Patients Enrolled
7 Trials studying Glaucoma
4,209 Patients Enrolled for Glaucoma
~10 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top